Peanut Allergy Patch Treatment, US Approval Application Countdown

DBV Technologies S.A. (NASDAQ: DBVT), a clinical-stage biotech company, presented additional data from its VITESSE Phase 3 trial in 4–7-year-old children with peanut allergy at the AAAAI 2026 Annual Meeting. The data showed statistically significant improvements in tolerated peanut dose and response rates versus placebo, along with a favorable safety profile characterized mainly by mild, localized skin reactions. The company also confirmed plans to submit a Biologics License Application (BLA) for the Viaskin Peanut patch to the U.S. Food and Drug Administration in the first half of 2026.

In its 2025 audited financial results and business update, DBV highlighted clinical progress of Viaskin Peanut in infants and young children. Through a private placement of up to $306.9 million (approximately KRW 400 billion) and an at-the-market (ATM) program raising $150 million (approximately KRW 200 billion), the company increased its cash position to $194.2 million (approximately KRW 250 billion). This funding runway is expected to support operations through the second quarter of 2027 under the current business plan centered on Viaskin Peanut.

The U.S. FDA previously agreed that the safety-exposure data from VITESSE Phase 3 are sufficient to support a BLA review for 4–7-year-olds, enabling DBV to move its 4–7-year submission target to the first half of 2026. The company is also preparing a BLA for the 1–3-year-old indication via the accelerated approval pathway in the second half of 2026. By securing its financing structure—up to $306.9 million in private placement and additional ATM issuances—DBV has extended its cash runway into late 2026. Following the positive clinical updates, several brokerages have raised their U.S. American Depositary Receipt (ADR) price targets to around $45, reflecting heightened market interest.

Headquartered in Montrouge, France, DBV Technologies is developing food allergy therapies using its proprietary Viaskin transdermal immunotherapy platform. Its lead asset, the Viaskin Peanut patch, is currently under regulatory review in both the U.S. and Europe for pediatric patients with peanut allergy. The company’s mid- to long-term strategy and capital allocation are effectively focused on obtaining regulatory approvals and launching this product.